The role of multi-drug resistance p-glycoprotein in glucocorticoid function: Studies in animals and relevance in humans

European Journal of Pharmacology

Volumn 583, Issue 2-3, 2008, Pages 263-271

  Pariante, Carmine M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Endothelial; Glucocorticoid; Multi drug resistance p glycoprotein; neurones; Psychopharmacological

Indexed keywords

ALDOSTERONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CARRIER PROTEIN; CORTICOSTERONE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; DESIPRAMINE; DEXAMETHASONE; DOXEPIN; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR ANTAGONIST; GLYCOPROTEIN P; HYDROCORTISONE; MESSENGER RNA; MIFEPRISTONE; MIRTAZAPINE; PAROXETINE; PREDNISOLONE; PROGESTERONE; RU 40555; TRIMIPRAMINE; UNCLASSIFIED DRUG; VENLAFAXINE;

AMYGDALOID NUCLEUS; AUTORADIOGRAPHY; BLOOD BRAIN BARRIER; BRAIN METABOLISM; CORTICOSTEROID METABOLISM; DRUG BRAIN LEVEL; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG TRANSPORT; ENDOTHELIUM CELL; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; ISOTOPE LABELING; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW;

ANIMALS; ANTIDEPRESSIVE AGENTS; DRUG RESISTANCE, MULTIPLE; GLUCOCORTICOIDS; HUMANS; MENTAL DISORDERS; MICE; MICE, KNOCKOUT; P-GLYCOPROTEINS; SPECIES SPECIFICITY;

EID: 40849111650     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.11.067     Document Type: Review

References (70)

1. Avella J., Lehrer M., Katz M., and Minden E. Two cases involving clomipramine intoxication. J. Anal. Toxicol. 28 (2004) 504-508
2. Becquemont L., Camus M., Eschwege V., Barbu V., Rey E., Funck-Brentano C., and Jaillon P. Lymphocyte P-glycoprotein expression and activity before and after rifampicin in man. Fundam. Clin. Pharmacol. 14 (2000) 519-525
3. Beery E., Middel P., Bahn A., Willenberg H.S., Hagos Y., Koepsell H., Bornstein S.R., Muller G.A., Burckhardt G., and Steffgen J. Molecular evidence of organic ion transporters in the rat adrenal cortex with adrenocorticotropin-regulated zonal expression. Endocrinology 144 (2003) 4519-4526
4. Bickel M.H., Brochon R., Friolet B., Herrmann B., and Stofer A.R. Clinical and biochemical results of a fatal case of desipramine intoxication. Psychopharmacologia 10 (1967) 431-436
5. Bolo N.R., Hode Y., Nedelec J.F., Laine E., Wagner G., and Macher J.P. Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology 23 (2000) 428-438
6. Bourgeois S., Gruol D.J., Newby R.F., and Rajah F.M. Expression of an mdr gene is associated with a new form of resistance to dexamethasone-induced apoptosis. Mol. Endocrinol. 7 (1993) 840-851
7. Brooksbank B.W., Brammall M.A., and Shaw D.M. Estimation of cortisol, cortisone and corticosterone in cerebral cortex, hypothalamus and other regions of the human brain after natural death and after death by suicide. Steroids Lipids Res. 4 (1973) 162-183
8. Chengyun D., Guoming L., Elia M., Catania M.V., and Qunyuan X. Expression of multidrug resistance type 1 gene (MDR1) P-glycoprotein in intractable epilepsy with different aetiologies: a double-labelling and electron microscopy study. Neurol. Sci. 27 (2006) 245-251
9. de Kloet E.R., Vreugdenhil E., Oitzl M.S., and Joels M. Brain corticosteroid receptor balance in health and disease. Endocr. Rev. 19 (1998) 269-301
10. Ebinger M., and Uhr M. ABC drug transporter at the blood-brain barrier: effects on drug metabolism and drug response. Eur. Arch. Psychiatry Clin. Neurosci. 256 (2006) 294-298
11. Farrell R.J., Menconi M.J., Keates A.C., and Kelly C.P. P-glycoprotein-170 inhibition significantly reduces cortisol and ciclosporin efflux from human intestinal epithelial cells and T lymphocytes. Aliment. Pharmacol. Ther. 16 (2002) 1021-1031
12. Felix R.A., and Barrand M.A. P-glycoprotein expression in rat brain endothelial cells: evidence for regulation by transient oxidative stress. J. Neurochem. 80 (2002) 64-72
13. Grauer M.T., and Uhr M. P-glycoprotein reduces the ability of amitriptyline metabolites to cross the blood brain barrier in mice after a 10-day administration of amitriptyline. J. Psychopharmacol. 18 (2004) 66-74
14. Herr A.S., Wochnik G.M., Rosenhagen M.C., Holsboer F., and Rein T. Rifampicin is not an activator of glucocorticoid receptor. Mol. Pharmacol. 57 (2000) 732-737
15. Higgins C.F. Multiple molecular mechanisms for multidrug resistance transporters. Nature 446 (2007) 749-757
16. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23 (2000) 477-501
17. Jaffrezou J.P., Chen G., Duran G.E., Muller C., Bordier C., Laurent G., Sikic B.I., and Levade T. Inhibition of lysosomal acid sphingomyelinase by agents which reverse multidrug resistance. Biochim. Biophys. Acta 1266 (1995) 1-8
18. Karssen A.M., Meijer O.C., van der Sandt I., Lucassen P.J., de Lange E.C., de Boer A.G., and de Kloet E.R. Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. Endocrinology 142 (2001) 2686-2694
19. Karssen A.M., Meijer O.C., van der Sandt I., de Boer A.G., de Lange E.C., and de Kloet E.R. The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone. J. Endocrinol. 175 (2002) 251-260
20. Karssen A.M., Meijer O., Pons D., and de Kloet E.R. Localization of mRNA expression of P-glycoprotein at the blood-brain barrier and in the hippocampus. Ann. N. Y. Acad. Sci. 1032 (2004) 308-311
21. Karssen A.M., Meijer O.C., Berry A., Sanjuan P.R., and de Kloet E.R. Low doses of dexamethasone can produce a hypocorticosteroid state in the brain. Endocrinology 146 (2005) 5587-5595
22. Kralli A., and Yamamoto K.R. An FK506-sensitive transporter selectively decreases intracellular levels and potency of steroid hormones. J. Biol. Chem. 271 (1996) 17152-17156
23. Kurowski C., and Berthold F. Presence of classical multidrug resistance and P-glycoprotein expression in human neuroblastoma cells. Ann. Oncol. 9 (1998) 1009-1014
24. Kwan P., Sills G.J., Butler E., Gant T.W., Meldrum B.S., and Brodie M.J. Regional expression of multidrug resistance genes in genetically epilepsy-prone rat brain after a single audiogenic seizure. Epilepsia 43 (2002) 1318-1323
25. Lazarowski A., Caltana L., Merelli A., Rubio M.D., Ramos A.J., and Brusco A. Neuronal mdr-1 gene expression after experimental focal hypoxia: a new obstacle for neuroprotection?. J. Neurol. Sci. 258 (2007) 84-92
26. Lee G., Dallas S., Hong M., and Bendayan R. Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol. Rev. 53 (2001) 569-596
27. Leschziner G.D., Andrew T., Pirmohamed M., and Johnson M.R. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J. 7 (2007) 154-179
28. Marsaud V., Mercier-Bodard C., Fortin D., Le Bihan S., and Renoir J.M. Dexamethasone and triamcinolone acetonide accumulation in mouse fibroblasts is differently modulated by the immunosuppressants cyclosporin A, FK506, rapamycin and their analogues, as well as by other P-glycoprotein ligands. J. Steroid Biochem. Mol. Biol. 66 (1998) 11-25
29. Medh R.D., Lay R.H., and Schmidt T.J. Agonist-specific modulation of glucocorticoid receptor-mediated transcription by immunosuppressants. Mol. Cell. Endocrinol. 138 (1998) 11-23
30. Meijer O.C., de Lange E.C., Breimer D.D., de Boer A.G., Workel J.O., and de Kloet E.R. Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice. Endocrinology 139 (1998) 1789-1793
31. Merry S., Hamilton T.G., Flanigan P., Freshney R.I., and Kaye S.B. Circumvention of pleiotropic drug resistance in subcutaneous tumours in vivo with verapamil and clomipramine. Eur. J. Cancer 27 (1991) 31-34
32. Miller A.H., Spencer R.L., Pulera M., Kang S., McEwen B.S., and Stein M. Adrenal steroid receptor activation in rat brain and pituitary following dexamethasone: implications for the dexamethasone suppression test. Biol. Psychiatry 32 (1992) 850-869
33. Muller M.B., Keck M.E., Binder E.B., Kresse A.E., Hagemeyer T.P., Landgraf R., Holsboer F., and Uhr M. ABCB1 (MDR1)-type P-glycoproteins at the blood-brain barrier modulate the activity of the hypothalamic-pituitary-adrenocortical system: implications for affective disorder. Neuropsychopharmacology 28 (2003) 1991-1999
34. Pariante C.M. Glucocorticoid receptor function in vitro in patients with major depression. Stress 7 (2004) 209-219
35. Pariante C.M. The glucocorticoid receptor: part of the solution or part of the problem?. J. Psychopharmacol. 20 (2006) 79-84
36. Pariante C.M., and Miller A.H. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol. Psychiatry 49 (2001) 391-404
37. Pariante C.M., Pearce B.D., Pisell T.L., Owens M.J., and Miller A.H. Steroid-independent translocation of the glucocorticoid receptor by the antidepressant desipramine. Mol. Pharmacol. 52 (1997) 571-581
38. Pariante C.M., Makoff A., Lovestone S., Feroli S., Heyden A., Miller A.H., and Kerwin R.W. Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transporters. Br. J. Pharmacol. 134 (2001) 1335-1343
39. Pariante C.M., Pearce B.D., Pisell T.L., Su C., and Miller A.H. The steroid receptor antagonists RU40555 and RU486 activate glucocorticoid receptor translocation and are not excreted by the steroid hormones transporter in L929 cells. J. Endocrinol. 169 (2001) 309-320
40. Pariante C.M., Hye A., Williamson R., Makoff A., Lovestone S., and Kerwin R.W. The antidepressant clomipramine regulates cortisol intracellular concentrations and glucocorticoid receptor expression in fibroblasts and rat primary neurones. Neuropsychopharmacology 28 (2003) 1553-1561
41. Pariante C.M., Kim R.B., Makoff A., and Kerwin R.W. Antidepressant fluoxetine enhances glucocorticoid receptor function in vitro by modulating membrane steroid transporters. Br. J. Pharmacol. 139 (2003) 1111-1118
42. Pariante C.M., Thomas S.A., Lovestone S., Makoff A., and Kerwin R.W. Do antidepressants regulate how cortisol affects the brain? 2003 Curt Richter Award Paper. Psychoneuroendocrinology 29 (2004) 423-447
43. Raison C.L., and Miller A.H. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am. J. Psychiatry 160 (2003) 1554-1565
44. Regina A., Koman A., Piciotti M., El Hafny B., Center M.S., Bergmann R., Couraud P.O., and Roux F. Mrp1 multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells. J. Neurochem. 71 (1998) 705-715
45. Rochat B., Baumann P., and Audus K.L. Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium. Brain Res. 831 (1999) 229-236
46. Saitoh H., Hatakeyama M., Eguchi O., Oda M., and Takada M. Involvement of intestinal P-glycoprotein in the restricted absorption of methylprednisolone from rat small intestine. J. Pharm. Sci. 87 (1998) 73-75
47. Sanchez E.R., Hu J.L., Zhong S., Shen P., Greene M.J., and Housley P.R. Potentiation of glucocorticoid receptor-mediated gene expression by heat and chemical shock. Mol. Endocrinol. 8 (1994) 408-421
48. Schinkel A.H. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv. Drug Deliv. Rev. 36 (1999) 179-194
49. Schinkel A.H., Wagenaar E., van D.L., Mol C.A., and Borst P. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest 96 (1995) 1698-1705
50. Shabbits J.A., Krishna R., and Mayer L.D. Molecular and pharmacological strategies to overcome multidrug resistance. Expert. Rev. Anticancer Ther. 1 (2001) 585-594
51. Stormer E., von Moltke L.L., Perloff M.D., and Greenblatt D.J. P-glycoprotein interactions of nefazodone and trazodone in cell culture. J. Clin. Pharmacol. 41 (2001) 708-714
52. Sunshine I., and Baeumler J. A fatal case of poisoning with amitriptyline. Nature 199 (1963) 1103-1104
53. Szabo D., Szabo Jr. G., Ocsovszki I., Aszalos A., and Molnar J. Anti-psychotic drugs reverse multidrug resistance of tumor cell lines and human AML cells ex-vivo. Cancer Lett. 139 (1999) 115-119
54. Ueda K., Okamura N., Hirai M., Tanigawara Y., Saeki T., Kioka N., Komano T., and Hori R. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J. Biol. Chem. 267 (1992) 24248-24252
55. Uhr M., and Grauer M.T. abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J. Psychiatr. Res. 37 (2003) 179-185
56. Uhr M., Steckler T., Yassouridis A., and Holsboer F. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 22 (2000) 380-387
57. Uhr M., Holsboer F., and Muller M.B. Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins. J. Neuroendocrinol. 14 (2002) 753-759
58. Uhr M., Grauer M.T., and Holsboer F. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol. Psychiatry 54 (2003) 840-846
59. Uhr M., Grauer M.T., Yassouridis A., and Ebinger M. Blood-brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in p-glycoprotein (abcb1ab) knock-out mice and controls. J. Psychiatr. Res. 41 (2007) 179-188
60. Upton R.N. Cerebral uptake of drugs in humans. Clin. Exp. Pharmacol. Physiol. 34 (2007) 695-701
61. van Kalken C.K., Broxterman H.J., Pinedo H.M., Feller N., Dekker H., Lankelma J., and Giaccone G. Cortisol is transported by the multidrug resistance gene product P-glycoprotein. Br. J. Cancer 67 (1993) 284-289
62. Varga A., Nugel H., Baehr R., Marx U., Hever A., Nacsa J., Ocsovszky I., and Molnar J. Reversal of multidrug resistance by amitriptyline in vitro. Anticancer Res. 16 (1996) 209-211
63. Volk H.A., Burkhardt K., Potschka H., Chen J., Becker A., and Loscher W. Neuronal expression of the drug efflux transporter P-glycoprotein in the rat hippocampus after limbic seizures. Neuroscience 123 (2004) 751-759
64. Weber C.C., Kressmann S., Ott M., Fricker G., and Muller W.E. Inhibition of P-glycoprotein function by several antidepressants may not contribute to clinical efficacy. Pharmacopsychiatry 38 (2005) 293-300
65. Weber C.C., Eckert G.P., and Muller W.E. Effects of antidepressants on the brain/plasma distribution of corticosterone. Neuropsychopharmacology 31 (2006) 2443-2448
66. Webster J.I., and Carlstedt-Duke J. Involvement of multidrug resistance proteins (MDR) in the modulation of glucocorticoid response. J. Steroid Biochem. Mol. Biol. 82 (2002) 277-288
67. Weiss J., Dormann S.M., Martin-Facklam M., Kerpen C.J., Ketabi-Kiyanvash N., and Haefeli W.E. Inhibition of P-glycoprotein by newer antidepressants. J. Pharmacol. Exp. Ther. 305 (2003) 197-204
68. Xia Z., Bergstrand A., DePierre J.W., and Nassberger L. The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. J. Biochem. Mol. Toxicol. 13 (1999) 338-347
69. Yates C.R., Chang C., Kearbey J.D., Yasuda K., Schuetz E.G., Miller D.D., Dalton J.T., and Swaan P.W. Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm. Res. 20 (2003) 1794-1803
70. Yau J.L., Noble J., Thomas S., Kerwin R., Morgan P.E., Lightman S., Seckl J.R., and Pariante C.M. The antidepressant desipramine requires the ABCB1 (Mdr1)-Type p-glycoprotein to upregulate the glucocorticoid receptor in mice. Neuropsychopharmacology 32 (2007) 2520-2529